Neratinib has been shown to significantly block MST1 activation in β-cells and islets [57], implying that Neratinib has demonstrated potential as a clinically viable treatment for targeting ovarian cancer peritoneal metastases in the future. Here, MST1 is linked to ovarian cancer.